 In addition, Catalyst expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 of the number of shares of common stock offered in the public offering. All of the shares in the offering are being offered by Catalyst. Catalyst anticipates using the net proceeds from this offering for general corporate purposes, which may include research and development activities in its complement program, clinical and manufacturing activities for marzeptacog alfa and dalcinonacog alfa, other research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs. 